Topical pimecrolimus: A new horizon for vitiligo treatment?

Journal of Dermatological Treatment

Volumn 17, Issue 6, 2006, Pages 338-342

  Şendur, Neslihan ^a   Karaman, Göksun ^a   Saniç, Nagehan ^a   Şavk, Ekin ^a  

^a ADNAN MENDERES UNIVERSITY   (Turkey)

Author keywords

Pimecrolimus; Therapy; Vitiligo

Indexed keywords

PIMECROLIMUS;

ADOLESCENT; ADULT; APPLICATION SITE BURNING; APPLICATION SITE DISCOMFORT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; FEMALE; HUMAN; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; SAMPLE SIZE; SCHOOL CHILD; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VITILIGO;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGE FACTORS; CHILD; DERMATOLOGIC AGENTS; DOSAGE FORMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME; VITILIGO;

EID: 34250204879     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630601028711     Document Type: Article

References (25)

1. Braun-Falco O, Plewing G, Wolff HH. Dermatology. 4th ed. Berlin and Heidelberg: Springer-Verlag; 2000.
2. Ortonne JP. Vitiligo and other disorders of hypopigmentation. In: Bolognia JB, Jorizzo JL, Rapini RP, editors, Dermatology. Spain: Elsevier Science; 2003. p. 947-54.
3. Mosher DB, Fitzpatrick TB, Ortonne JP. Hypomelanoses and hypermelanoses. In: Fitzpatrick TB, Eisen AZ, Wolf K, Freedberg IM, editors. Dermatology in general medicine. 5th ed. New York: Mc Graw-Hill; 1999. p. 954-60.
4. Kovacs SO. Vitiligo. J Am Acad Dermatol. 1998;38:647-66.
5. Kostovic K, Pasic A. New treatment modalities for vitiligo: Focus on topical immunomodulators. Drugs. 2005;65:447-59.
6. Silverberg NB, Lin P, Travis L, Farley-Li J, Mancini AJ, Wagner AM, et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: A review of 57 cases. J Am Acad Dermatol. 2004;51:760-6.
7. Njoo MD, Bossuyt PM, Westerhof W. Management of vitiligo. Results of a questionnaire among dermatologists in The Netherlands. Int J Dermatol. 1999;38:866-72.
8. Sharma N, Koranne RV, Singh RK. Psychiatric morbidity in psoriasis and vitiligo: A comparative study. J Dermatol. 2001;28:419-23.
9. Mattoo SK, Handa S, Kaur I, Gupta N, Malhotra R. Psychiatric morbidity in vitiligo and psoriasis: A comparative study from India. J Dermatol. 2001;28:424-32.
10. Gupta AK, Chow M. Pimecrolimus: A review. J Eur Acad Dermatol Venereol. 2003;17:493-503.
11. Paul C, Graeber M, Stuetz A. Ascomycins: Promising agents for the treatment of inflammatory skin diseases. Expert Opin Investig Drugs. 2000;9:69-77.
12. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology. Br J Dermatol. 1999;141:263-73.
13. Grimes PE, Morris R, Avaniss-Aghajani E, Soriano T, Meraz M, Metzger A. Topical tacrolimus therapy for vitiligo: Therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol. 2004;51:52-61.
14. Grimes PE. New insights and new therapies in vitiligo. JAMA. 2005;293:730-5.
15. Handa S, Pandhi R, Kaur I. Vitiligo: A retrospective comparative analysis of treatment modalities in 500 patients. J Dermatol. 2001;28:461-6.
16. Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol. 2000;42:245-53.
17. Tjioe M, Vissers WH, Gerritsen MJ. Topical macrolide immunomodulators: A role in the treatment of vitiligo? Am J Clin Dermatol. 2006;7:7-12.
18. Gribetz C, Ling M, Lebwohl M, Pariser D, Draelos Z, Gottlieb AB, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double-blind randomized study. J Am Acad Dermatol. 2004;51:731-8.
19. Kreuter A, Gambichler T, Breuckmann F, Pawlak FM, Stucker M, Bader A, et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol. 2004;51:407-10.
20. Queille-Roussel C, Graeber M, Thurston M, Lachapelle JM, Decroix J, de Cuyper C, et al. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermatitis. 2000;42:349-50.
21. Smith DA, Tofte SJ, Hanifin JM. Repigmentation of vitiligo with topical tacrolimus. Dermatology. 2002;205:301-3.
22. Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol. 2002;47:789-91.
23. Mayoral FA, Gonzales C, Shah NS, Arciniegas C. Repigmentation of vitiligo with pimecrolimus cream: A case report. Dermatology. 2003;207:322-3.
24. Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol. 2003;139:581-5.
25. Coskun B, Saral Y, Turgut D. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol. 2005;15:88-91.